Capricor Therapeutics Faces Securities Class Action over Statistical Plan Changes

Capricor Therapeutics, Inc. (NASDAQ: CAPR) is now the target of a securities class action lawsuit filed by Kaplan Fox & Kilsheimer LLP. The complaint covers investors who acquired the company's securities between December 17, 2025, and July 26, 2026. The legal action centers on allegations that the company failed to disclose material information regarding its pre-specified statistical analysis plan (SAP) for the Dermamiocel Biologics License Application (BLA).

The core of the dispute involves the FDA's release of briefing documents on July 27, 2026, prior to its Advisory Committee meeting. According to the complaint, these documents revealed that Capricor had modified its SAP, a version that was neither submitted to the FDA for review before the BLA submission nor agreed upon. This revelation triggered a sharp market reaction, with the stock price falling by $12.70, or 64%, to close at $7 per share on that date.

Legal Deadline for Lead Plaintiff Selection

Investors who purchased Capricor shares during the specified class period have until September 28, 2026, to petition the court for appointment as lead plaintiff. This deadline was highlighted in a notice distributed by the law firm, which advises that individuals do not need to seek lead plaintiff status to participate in any potential recovery. The firm, which has represented clients in high-profile securities cases recovering billions of dollars, is handling this matter as part of its broader litigation practice in federal courts.

Regulatory Disclosure Triggers Market Reaction

The immediate financial impact on Capricor was significant. The 64% decline on July 27, 2026, represents a substantial loss in market capitalization that the plaintiffs argue was caused by the delayed disclosure of the SAP changes. The complaint suggests that the company's failure to align the final SAP with regulatory expectations and internal disclosures misled the market. This incident underscores the regulatory risks associated with clinical trial data analysis and the importance of transparent communication with the FDA and investors.

Investor Rights and Litigation Process

The litigation process involves identifying the most representative plaintiff to lead the class, a step that determines the direction of the case. Kaplan Fox & Kilsheimer LLP, which operates offices in New York, Oakland, Los Angeles, Chicago, and New Jersey, encourages affected investors to review their holdings. The firm notes that contacting them does not create an attorney-client relationship but provides a channel for legal consultation. As the case progresses, the focus will remain on the specific disclosures made during the class period and their impact on share price stability.